ClinicalTrials.gg
RecruitingNCT07199361Updated Oct 27, 2026

Uncovering the Mechanism of Pain Relief by Peripheral Transcutaneous Magnetic Stimulation

An interventional study of Peripheral Transcutaneous Magnetic Stimulation from MagVenture in Post-Surgical Pain, Chronic and Post-traumatic Pain, Chronic, sponsored by Florida International University. Recruiting at 1 site in United States. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Florida International University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Mar 2025, registered Sep 2025).
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.

Planned enrollment
728th of 1,099
50 · median 76
Started
2025
with 48 others
No phase
373 of 1,181
68 open now
Primary completion
2028-01
later than 193 of 236 live
Registered
1,104th of 1,181
by date

Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 728th largest by planned enrollment of the 1,099 interventional ones that give a count, is one of 49 that started in 2025, is one of 373 with no phase, reaches primary completion later than 193 of the 236 other live ones, and was the 1,104th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

199 more — sign in →

All 204 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,181 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

This research aims to uncover the Mechanisms of pain relief through the FDA-cleared peripheral transcutaneous magnetic stimulation (pTMS) device by MagVenture. 50 people with chronic pain (post-surgical or post-traumatic) will be identified and recruited. The eligibility for participation in the study will be evaluated by a series of pain and mental health questionnaires followed by quantitative sensory testing (QST) to assess response to noxious heat, cold, and pressure stimuli. Blood will be drawn to isolate plasma, serum, and leukocytes. Participants will then undergo pTMS at the site of pain for four consecutive days. At the end of the therapy, pain testing will be done again, followed by blood withdrawal to assess the changes in plasma and leukocyte levels of mediators of pain. It is anticipated that pTMS will increase mediators of pain relief and reduce inflammatory mediators. Risks: It is possible that a few participants may not respond to pTMS therapy. However, plasma analysis of mediators of pain may help stratify these participants into responders vs. non-responders. Risks associated with the study are minimal and mainly involve discomfort associated with pain testing. The importance of knowledge gained includes understanding pain relief mechanisms by medical devices such as pTMS, which will result in better pain management.

Read the detailed description

Chronic pain (pain lasting ≥3 months) is a debilitating condition associated with depression, dementia, increased risk of suicide, decreased productivity, and substance abuse. Opioids continue to be a crucial part of pain management. However, the misuse of prescription opioids has led to a shift towards injectable opioids such as heroin, with nearly 80% of new heroin users reporting prior use of prescription opioids. Further, co-morbid substance abuse can exacerbate pain symptoms despite pharmaceutical treatment, revealing the limitations of current pain management strategies. Due to tolerance, people with a history of opioid dependence often need higher doses of opioids to treat acute pain and long-term opioid use paradoxically worsens chronic pain. From a public health perspective, there is an increased chance of transmitting and acquiring hepatitis B and C due to opioid use-related engagement in risky behaviors. Moreover, the economic burden of untreated pain in the US is estimated to be more than $100 billion per year. Therefore, there is an urgent need to develop novel therapeutic strategies and reduce reliance on opioids.

Peripheral Transcutaneous Magnetic Stimulation (pTMS) is a non-invasive method of relieving pain by stimulating the target area with magnetic pulses. The magnetic field pulse passing into the body induces a voltage difference between any two points, which creates an electric field and causes electrons to flow between these two points. The magnetic field can penetrate deep tissue, such as spinal nerve roots or muscles. No mechanical contact is necessary, making pTMS applicable to patients with extreme hypersensitivity or allodynia to skin touch. pTMS is FDA-cleared for post-traumatic and post-surgical chronic pain. However, to date, no clear evidence has emerged about pTMS's potential mechanism of pain relief, which has moderated its applicability and acceptability.

The study will require recruiting patients over the phone, followed by an on-site visit, which includes patient interaction, blood collection, pain study, performing pTMS therapy at the site of pain, and patient monitoring. Three more on-site visits on consecutive days will include pTMS therapy. The last (fourth) visit will include specimen collection and a pain study. The first and the fourth visits will take 2.5 hours, while the second and the third visits will require 30 minutes. The participants will be followed over the phone every 30 days till the completion of the study to inquire about their wellness.

03

Conditions studied

  • Post-Surgical Pain, Chronic
  • Post-traumatic Pain, Chronic

Keywords

  • Peripheral Transcutaneous Magnetic Stimulation
  • Post-Traumatic and Post-Surgical Chronic Pain
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of chronic peripheral pain secondary to trauma or surgery. Age 19 - 80; the lower end of this age range was chosen to capture young adults with pain, and participants over 80 years are increasingly likely to meet one or more exclusion criteria.

Currently receiving pain medication Chronic pain must self-report peripheral pain, more than once per week, for at least three consecutive months

Exclusion criteria

Exclusion Criteria:

  • Implanted Electronic Devices and / or Conductive Objects in or near the head: Patients who have an implanted device that is activated or controlled in any way by physiological signals (examples: deep brain stimulators, cochlear implants, and vagus nerve stimulators).

Non-Removable Metallic Objects near the coil: Patients who have conductive, ferromagnetic, or other magnetic-sensitive metals implanted in their head or within 30 cm of the treatment coil (examples: cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, and bullet fragments). F NOTE: Standard amalgam dental fillings are not affected by the magnetic field and are acceptable in patients.

Active microbial infections may alter the quantity or quality of blood inflammatory cells such as monocytes and neutrophils.

Positive Urine Drug test: (COC/AMP/OPI/mAMP/PCP/BAR/BZO/MTD/MDMA/OXY/PPX/BUP/TCA) Use of any medication other than pain medications. However, participants will not be excluded or asked to withdraw from medications used for pain management since temporary withdrawal from these medications could affect pain measures (exceptions will be therapies such as methadone or buprenorphine used to treat opioid addiction). Only those who have been stable on these medications for at least 60 days will be included. All patient medications used for at least 60 days prior to participation will be recorded and controlled in statistical analyses as needed.

Systemic rheumatic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus). These rheumatologic conditions will be excluded due to their characteristic.

Cachexia (wasting syndrome) and severe frailty as determined by the Groningen Frailty Index (score >4). This exclusion is in place to protect against the stress of experimental pain testing.

Uncontrolled hypertension (i.e. SBP/DBP of >140/90) or cardiovascular or peripheral arterial disease. These exclusions are in place primarily for safety reasons because the cold pressor task represents a cardiovascular challenge. However, uncontrolled hypertension can also affect pain perception, which is another reason for excluding these individuals.

Poorly controlled diabetes ( > 8%) for both safety reasons and because diabetic neuropathy could alter pain perception.

Neurological disease (e.g. Parkinson's, multiple sclerosis). Serious psychiatric disorder requiring hospitalization within the past 12 months or characterized by active suicidal ideation. Any participant deemed to be actively suicidal upon study screening will be escorted to the emergency room and evaluated by the Psychiatry Service.

A diminished cognitive function that would interfere with the understanding of study procedures. The Mini-Mental Status Exam () will be administered to ensure that participants are free of cognitive impairment that would compromise study participation. MMSE \<18 will be excluded.

Pregnancy

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Post-traumatic or post-surgical chronic pain

    Arm Description: 50 Participants with post-surgical or post-traumatic chronic pain below the neck will be administered peripheral transcutaneous magnetic stimulation at the site of pain for 13 minutes for 4 consecutive days. Participants will be male or female between the ages of 19 and 80 years.

    Device: Peripheral Transcutaneous Magnetic Stimulation from MagVenture

Interventions

  • DevicePeripheral Transcutaneous Magnetic Stimulation from MagVenture

    MagVenture Pain Therapy System: It is an FDA-cleared magnetic stimulator system that provides brief and focused magnetic pulses to non-invasively stimulate peripheral nerves and provide relief of chronic intractable, post-traumatic, and post-surgical pain for patients 18 years or older. It is a relatively new technique in the US for pain relief in the clinical setting and thus not very widespread yet. Evidence shows Magnetic Peripheral Nerve Stimulation to have a promising average pain relief of up to 87%\*. Using magnetic pulses, MagVenture Pain Therapy engages sensory, pain, and motor fibers mechanistically to recondition the central nervous system by eliminating noxious pain signals to the brain, reducing chronic neuropathic pain for responsive patients. \*Bedder M, Parker L.: Magnetic Peripheral Nerve Stimulation (mPNS) for Chronic Pain, 2023

06

What researchers measure

Primary outcomes

  1. Pressure Pain Assessment

    Pressure Pain Threshold. A handheld probe (Algomed, Medoc) with a small (less than ½ inch wide) rubber tip will be used to apply pressure to the participant's forearm and shoulder. The pressure will slowly increase, and the participant will be asked to click a button when they first feel pain as a result of the pressure stimulation. The pressure will be removed as soon as the participant presses this button. This particular algometer will be used because it provides the examiner with visual feedback to maintain a consistent application rate, which is critical for maintaining high inter-examiner reliability. To assess the pressure pain threshold, the examiner will apply a constant rate of pressure, and the participant will be instructed to press a button when the sensation first becomes painful, at which time the device records the pressure in kilopascals. Higher kilopascals would suggest less pressure pain.

    Time frame: 1. On Day 1 (Baseline) 2. On Day 4 (post therapy)

  2. Thermal (Heat) pain

    Thermal (Heat) (Threshold, pain, and tolerance) will be assessed using TSA2 Air device from Medoc: A slowly increasing heat stimulus that the participant can terminate by pressing a button when it becomes painful or intolerable. The participant would press the button when they first feel warm (threshold), pain, or can no longer tolerate the heat. Lower heat indices indicate higher thermal sensitivity.

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post therapy)

  3. Thermal (Cold) Pain

    Thermal (Cold) (Threshold, pain, and tolerance) will be assessed using TSA2 Air device from Medoc: A slowly decreasing cold stimulus that the participant can terminate by pressing a button when it becomes painful or intolerable. The participant would press the button when they first feel cold (threshold), pain, or can no longer tolerate the cold. Higher cold indices indicate higher thermal sensitivity.

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post therapy)

  4. Temporal Heat Summation

    Temporal heat summation will be measured using TSA2 Air device. A series of 5 brief heat pulses (about 2 seconds in duration) will be given, and the participant will be asked to rate how painful each heat pulse feels on a scale from 0 to 100. These heat pulses will be repeated at different temperatures (44° C, 46° C, and 48° C). The participant can stop the procedures at any time so that they do not experience unacceptable pain. Greater pain ratings indicate more pain

    Time frame: 1. On day 1 (Baseline) 2. On Day 4 (Post therapy)

  5. Conditioned Pain Modulation

    Conditioned pain modulation (CPM) will be tested by TSA2 Air Device. The standard thermode will be placed on the left hand, and the heat pain rating will be assessed at 46 degrees. Then the right hand will be immersed in cold water for 30 seconds. The Heat pain test will be performed again on the left hand to assess Pain modulation. A normal response would indicate a decrease in heat pain on the left hand after immersing the right hand in cold water.

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post Therapy)

Secondary outcomes

  1. McGill Pain Questionnaire-Short Form

    Description: 15 descriptors (11 sensory; 4 affective) using an intensity scale ranging from 0-3 on the pain scale (0 = no pain, 1 = mild pain, 2 = moderate pain, or 3 = severe pain) A higher number indicates more pain

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post therapy)

  2. Brief Pain Inventory

    A set of 4 Pain Questionnaire: Worst pain in last 24 hours: (1-10) Least pain in last 24 hours (1-10) Pain on average (1-10) Pain right now (1-10) Total possible score: 40 A higher number indicates more pain

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post therapy)

  3. Present Pain Index

    A pain score of current pain on the scale of 0-5 A higher number indicates more pain

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post therapy)

  4. Visual Analogue scale

    A visual pain scale of 1-100 A higher number indicates more pain

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post therapy)

  5. PHQ-9

    Patient Health Questionnaire (depression screening) Scores : 0-27 A higher number indicates greater depression

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post therapy)

  6. GAD-7

    General Anxiety Disorder 7 items scored between 0-3. Score: 0-21 A higher number indicates more anxiety

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post therapy)

  7. Vascular Reactivity Index (VRI)

    A vascular function test using the Vendys Endothelix device Measures Vascular function Score: 0-3 (VRI) The higher the number, the better the vascular function.

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post therapy)

  8. Measuring Endogenous Opioids in Plasma

    20 ml of blood will be drawn to isolate plasma and peripheral leukocytes in pg/ml. Lower endogenous opioids indicate more pain.

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post therapy)

  9. Measuring Inflammatory cytokines in Plasma

    A 20 ml blood sample will be collected, and plasma cytokines will be measured in mg/ml. Higher plasma cytokines indicate more pain

    Time frame: 1. On Day 1 (Baseline) 2. On Day 4 (Post Therapy)

  10. Measuring endogenous opioids in peripheral immune cells.

    A 20 ml blood sample will be collected, and endogenous opioids will be measured in pg/mg protein. Lower endogenous opioids would indicate more pain

    Time frame: 1. On day 1 (Baseline) 2. On day 4 (Post Therapy)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest in Chronic Pain. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party

Supporting information: Clinical study report

Time frame: Data requests can be submitted starting 9 months after article publication, and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis

Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2028, 34 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 34 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2025
First posted
Sep 30, 2025
StartActual
Mar 24, 2025
Primary completionEst.
Jan 25, 2028
CompletionEst.
Feb 25, 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07199361
Collaborators
Baptist Health South Florida
Responsible party
Dr. Saurabh Aggarwal (Associate Professor, Florida International University) — Principal investigator
First posted
Sep 30, 2025
Start date
Mar 24, 2025
Primary completion
Jan 25, 2028 (estimated)
Completion
Feb 25, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Associate Professor
Contact
saaggarw@fiu.edu
305-348-9634
Saurabh Aggarwal, MD., PhD
principal investigator · Florida International University
Patricia Junquera, MD
principal investigator · Florida International University and Baptist Health South Florida
Eduardo Icaza, MD
principal investigator · Baptist Health South Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion